A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT study

American Journal of Therapeutics

Volumn 18, Issue 1, 2011, Pages 14-22

  Boyce, Steven W ^a   Bandyk, Dennis F ^b   Bartholomew, John R ^c   Frame, James N ^d   Rice, Lawrence ^e  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d West Virginia University School of Medicine Charleston   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

argatroban; desirudin; direct thrombin inhibitor; heparin; heparin induced thrombocytopenia; thrombosis

Indexed keywords

ARGATROBAN; DESULFATOHIRUDIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; INFUSION SYSTEM; MALE; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; DISEASE PROGRESSION; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PIPECOLIC ACIDS; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RECOMBINANT PROTEINS; THROMBIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78751650013     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181f65503     Document Type: Article

References (36)

1. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028-1040.
2. Hirsh J. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. 2008;133:141-159.
3. Crespo EM, Oliveira GB, Honeycutt EF, et al. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J. 2009; 157:651-657.
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
5. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518-2524.
6. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. 2008;133: S340-S380.
7. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809-817.
8. Battistelli S, Genovese A, Gori T. Heparin-induced throm-bocytopenia in surgical patients. Am J Surg. 2010;199:43-51.
9. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest. 2005;127: S35-S45.
10. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004;164:361-369.
11. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet. 2002;359:294-302.
12. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost. 2001;27: 537-541.
13. Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
14. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
15. Lewis BE, Wallis DE, Leya F, et al. Argatroban anti-coagulation in patients with heparin-induced thrombo-cytopenia. Arch Intern Med. 2003;163:1849-1856.
16. Iprivask [package insert]. Hunt Valley MD: Canyon Pharmaceuticals, Inc. 2010.
17. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractio-nated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79:326-333.
18. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337: 1329-1335.
19. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 1995;333:757-763.
20. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation. 1994;89: 1557-1566
21. Randomized trial of intravenous heparin versus recombi-nant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation. 1994;90: 1631-1637
22. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med. 1996;335: 775-782.
23. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
24. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994;90:1624-1630.
25. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23:993-1003.
26. Lee LV. Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombol-ysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol. 1995;75:7-13.
27. van den Bos AA, Deckers JW, Heyndrickx GR, et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993;88:2058-2066.
28. McBane RD, Hassinger NL, Mruk JS, et al. Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin. Thromb Res. 2005;116: 525-532.
29. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol. 2004;17:105-125.
30. Hijikata-Okunomiya A, Okamoto S, Wanaka K. Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III. Thromb Res. 1990;59:967-977.
31. Braun PJ, Dennis S, Hofsteenge J, et al. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry (Mosc). 1988;27:6517-6522.
32. Frame JN, Rice L, Bartholomew J, et al. Rationale and design of the PREVENT-HIT Study: a randomized, open-label, pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocyto-penia with or without thrombosis. Clin Ther. 2010;32: 626-636.
33. Red Book. Ann Arbor, MI: Thomson Reuters; 2010.
34. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med. 2004;164:1961-1964.
35. Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest. 2007;131:1620-1622.
36. Levine RL. Finding haystacks full of needles: from Opus to Osler. Chest. 2005;127:1488-1490.